Takeda's Biologics License Application (BLA) for Dengue Vaccine Candidate ( TAK-003) Granted Priority Review by U.S. Food and Drug Administration
Frontiers | Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003
Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003) | PLOS Neglected Tropical Diseases
Cross-reactivity of T cell responses following TAK-003... | Download Scientific Diagram
Frontiers | Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003
The Lancet on Twitter: "NEW—Tetravalent dengue vaccine (TAK-003) was well tolerated and efficacious against symptomatic #dengue in children aged 4-16 years regardless of serostatus before immunisation: a randomised, placebo-controlled, phase 3 trial
TAK-003 - News, Articles etc. - European Pharmaceutical Review
PharmaShots. - • The submission is based on a P-III TIDES trial assessing TAK-003 (0.5ml, SC) vs PBO in 20,000+ healthy children & adolescents aged 4-16yrs. to prevent dengue fever of any
Takeda's Biologics License Application (BLA) for Dengue Vaccine Candidate ( TAK-003) Granted Priority Review by U.S. Food and Drug Administration - Headlines of Today
ABOUT DENGUE AND TAKEDA'S DENGUE VACCINE CANDIDATE (TAK-003)
Takeda's dengue vaccine prevents hospitalisations in TIDES trial
gemirdaypresentation
Structure of: (a) CYD -TDV (Dengvaxia); (b) TAK -003; (c) TV003 / TV005... | Download Scientific Diagram
Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination. - Abstract - Europe PMC
Takeda's tetravalent dengue vaccine (TAK-003) receives first global approval for use in Indonesia without need for pre-vaccination testing | Asia Research News
Drug Overview: TAK-003 - Research and Markets
Potential Impact of Takeda's Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy Results
TAK-003
Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003) | PLOS Neglected Tropical Diseases
Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents | NEJM
CONTRIBUTING TO THE FIGHT AGAINST DENGUE
TAK-003 vaccine: Trial shows Continued Protection against Dengue Fever - YouTube
